Table 3.
Association of diabetes-related variables with endpoints
| Characteristica | χ2 | HR (95% CI) | P-value |
|---|---|---|---|
| Efficacy endpoints | |||
| CV death, MI, or stroke | |||
| Diabetes | 108.78 | 1.66 (1.51–1.82) | <0.0001 |
| Baseline glucose (truncated)b | 67.22 | 1.12 (1.09–1.15) | <0.0001 |
| Baseline HbA1c (truncated)b | 90.72 | 1.30 (1.23–1.37) | <0.0001 |
| All-cause death | |||
| Diabetes | 78.87 | 1.84 (1.61–2.10) | <0.0001 |
| Baseline glucose (truncated)b | 83.47 | 1.21 (1.16–1.25) | <0.0001 |
| Baseline HbA1c (truncated)b | 75.14 | 1.40 (1.30–1.51) | <0.0001 |
| MI | |||
| Diabetes | 44.09 | 1.53 (1.35–1.73) | <0.0001 |
| Baseline glucose (truncated)b | 9.92 | 1.06 (1.02–1.10) | 0.0016 |
| Baseline HbA1c (truncated)b | 34.85 | 1.24 (1.15–1.33) | <0.0001 |
| Definite stent thrombosisc | |||
| Diabetes | 1.91 | 1.26 (0.91–1.77) | 0.1673 |
| Baseline glucose (truncated)b | 12.68 | 1.19 (1.08–1.31) | 0.0004 |
| Baseline HbA1c (truncated)b | 5.20 | 1.24 (1.03–1.50) | 0.0226 |
| Safety endpoints | |||
| Major bleeding | |||
| Diabetes | 48.13 | 1.41 (1.28–1.55) | <0.0001 |
| Baseline glucose | 14.91 | 1.03 (1.01–1.04) | 0.0001 |
| Baseline HbA1c | 20.39 | 1.07 (1.04–1.11) | <0.0001 |
| Non-CABG major bleeding | |||
| Diabetes | 14.50 | 1.38 (1.17–1.62) | 0.0001 |
| Baseline glucose | 9.78 | 1.04 (1.01–1.06) | 0.0018 |
| Baseline HbA1c | 0.03 | 1.00 (0.95–1.06) | 0.8676 |
| CABG-related major bleeding | |||
| Diabetes | 34.16 | 1.42 (1.26–1.60) | <0.0001 |
| Baseline glucose | 5.49 | 1.02 (1.00–1.04) | 0.0191 |
| Baseline HbA1c | 28.65 | 1.10 (1.06–1.14) | <0.0001 |
aGlucose and HbA1c values are treated as linear for the range of values for the safety endpoints.
bFor efficacy outcomes, glucose values <5 and >10 are treated as 5 and 10, respectively. For efficacy outcomes, HbA1c values >8 are treated as 8.
cOf the 11 289 patients who received a stent, 2520 had DM.